Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 265.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.36M |
| Shares Out | 13.12M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,908 |
| Open | 20.50 |
| Previous Close | 19.99 |
| Day's Range | 19.22 - 20.61 |
| 52-Week Range | 19.22 - 69.77 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 76.50 (+278.0%) |
| Earnings Date | n/a |
About GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Staffo...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GLSI stock is "Buy" and the 12-month stock price forecast is 76.50.
News
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low ...
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential Fo...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upc...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - October 20, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fid...
The Moonshot Investor: The Insider Track Strategy
Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subs...
A Controversial Moonshot Stock Just Got a Lot More Interesting
Studies have found that insiders outperform the market by 6-15%. Over a long period, that's an incredible achievement and worth understanding.
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
Greenwich LifeSciences Set to Join Russell 2000® Index
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer ...
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were pre...
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming th...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commerc...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting